长期应用托吡酯、丙戊酸钠对于血脂水平的影响

摘要/Abstract

摘要：

目的观察长期应用托吡酯、丙戊酸钠单药治疗对癫痫患者血脂水平的影响。方法连续入组长期单药应用丙戊酸钠控制良好的癫痫患者28例、单药应用托吡酯控制良好的癫痫患者30例，并选取健康对照60例，观察各组间血脂代谢指标的差异。结果丙戊酸钠组血清脂蛋白（a）水平显著高于托吡酯组（P<0.001）及健康对照组（P=0.003），而总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯水平较其他两组无明显差异。托吡酯组的总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、脂蛋白（a）、甘油三酯水平较对照组均未有显著差异。结论长期单药应用丙戊酸钠有可能增加癫痫患者脂蛋白（a）的水平，而长期单药应用托吡酯对于血脂水平影响并不明显。

文章导读： 本研究显示，长期应用丙戊酸钠能增加癫痫患者脂蛋白（a）的水平。

关键词: 托吡酯; 丙戊酸钠; 血脂

Abstract:

Objective To assess the effects of long-term topiramate and valproate sodium monotherapy on serum lipids in patients with epilepsy. Methods Fifty eight adult epilepsy patients who were on antiepileptic drug monotherapy (30 receiving topiramate and 28 receiving valproate sodium) for more than 12 months were recruited. Sixty age and sex matched healthy adults were enrolled in this study as the control group. Serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) and triglycerides (TG) were measured in all participants after overnight fasting. Results The group which received the valproate sodium monotherapy showed increased levels of serum lipoprotein(a) except for TC, LDL-C, HDL-C and TG (P>0.05) when compared to the group receiving topiramate (P<0.001) as well as the controls (P=0.003). The group receiving the topiramate monotherapy demonstrated insignificant changes in cholesterol (TC, LDL-C, HDL-C), TG and lipoprotein(a) levels in comparison with the control group. Conclusion Serum lipoprotein(a) level was substantially increased in epilpesy patients on a long-term monotherapy with valproate sodium, whereas long-term topiramate monotherapy might have a minor effect on serum lipids.

Key words: Topiramate; Valproate sodium; Serum lipids

夏曼1，郁金泰2，谭兰1，2. 长期应用托吡酯、丙戊酸钠对于血脂水平的影响[J]. 中国卒中杂志, 2013, 8(10): 786-790.

XIA Man*, YU Jin-Tai, TAN Lan.. Effects of Long-term Topiramate and Valproate Sodium Monotherapy on Serum Lipid Levels[J]. Chinese Journal of Stroke, 2013, 8(10): 786-790.

参考文献

1 中华医学会神经病学分会脑电图与癫痫学组. 抗癫痫药物应用专家共识[J]. 中华神经科杂志, 2011, 44:56-65.

2 Kwan P, Sander JW. The nature history of epilepsy:an epidemiological view[J]. J Neurol Neurosurg Psychiatry, 2004, 75:1376-1381.

3 Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis[J]. Epilepsia, 2012, 53:120-128.

4 贾建平, 陈生弟. 神经病学[M]. 第7版. 北京:人民卫生出版社, 2008:292.

5 贾建平, 陈生弟. 神经病学[M]. 第7版. 北京:人民卫生出版社, 2008:294-304.

6 贾建平, 陈生弟. 神经病学[M]. 第7版. 北京:人民卫生出版社, 2008:175-187.

7 陆再英, 钟南山. 内科学[M]. 第7版. 北京:人民卫生出版社, 2008:267-302.

8 陆再英, 钟南山. 内科学[M]. 第7版. 北京:人民卫生出版社, 2008:251-266.

9 陆再英, 钟南山. 内科学[M]. 第7版. 北京:人民卫生出版社, 2008:770-793.

10 Hamed SA, Hamed EA, Hamdy R, et al. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy[J]. Epilepsy Res, 2007, 74:183-192.

11 Aynaci FM, Orhan F, Orem A, et al. Effect of antiepileptic drugs on plasma lipoprotein(a) and other lipid levels in childhood[J]. J Child Neurol, 2001, 16:367-369.

12 Gurdasani D, Sjouke B, Tsimikas S, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease:the EPIC-Norfolk prospective population study[J]. Arterioscler Thromb Vasc Biol, 2012, 32:3058-3065.

13 Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases[J]. Biomed Res Int, 2013, 2013:650989.

14 Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease:a rationale for increased efforts to understand its pathophysiology and develop targeted therapies[J]. J Am Coll Cardiol, 2012, 60:716-721.

15 Morrell MJ, Isojarvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy[J]. Epilepsy Res, 2003, 54:189-199.

16 Sonmez FM, Demir E, Orem A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein(a), and liver enzymes[J]. J Child Neurol, 2006, 21:70-74.

17 Yilmaz E, Dosan Y, Gurgoze MK, et al. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children[J]. Acta Neurol Belg, 2001, 101:217-220.

18 Grosso S, Mostardini R, Piccini B, et al. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy[J]. Ann Pharmacother, 2009, 43:45-50.

19 Demircioglu S, Soylu A, Dirik E. Carbamazepine and valproic acid:effects on the serum lipids and liver functions in children[J]. Pediatr Neurol, 2000, 23:142-146.

20 Verrotti A, Domizio S, Angelozzi B, et al. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants[J]. J Paediatr Child Health, 1997, 33:242-245.

21 Voudris KA, Attilakos A, Katsarou E, et al. Early and persistent increase in serum lipoprotein(a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy[J]. Epilepsy Res, 2006, 70:211-217.

22 Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, et al. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism[J]. Epilepsia, 1999, 40:1761-1766.

23 Erem C, Deger O, Bostan M, et al. Plasma lipoprotein(a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects[J]. Actacardiologica, 1999, 54:77-81.

24 Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy[J]. Ann Neurol, 1998, 43:446-451.

25 Conover CA, Lee PD, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans[J]. J Clin Endocrinol Metab, 1992, 74:1355-1360.

26 Gibbons GF. The role of cytochrome P450 in the regulation of cholesterol biosynthesis[J]. Lipids, 2002, 37:1163-1170.

27 Kandutsch AA, Chen HW. Inhibition of cholesterol synthesis by oxygenated sterols[J]. Lipids, 1978, 13:704-707.

28 Mintzer S, Skidmore CT, Rankin SJ, et al. Conversion from enzyme-inducing antiepileptic drugs to topiramate:effects on lipids and C-reactive protein[J]. Epilepsy Res, 2012, 98:88-93.

29 Genc BO, Dogan EA, Dogan U, et al. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment[J]. J Clin Neurosci, 2010, 17:1256-1259.

30 Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs:a review of human studies[J]. Fundam Clin Pharmacol, 2000, 14:301-319.

31 Lopinto-Khoury C, Mintzer S. Antiepileptic drugs and markers of vascular risk[J]. Curr Treat Options Neurol, 2010, 12:300-308.

32 Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss:a review[J]. Epilepsy Res, 2011, 95:189-199.

[1]	中国卒中学会医疗质量管理与促进分会, 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组. 中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明[J]. 中国卒中杂志, 2024, 19(4): 440-451.
[2]	黄艳玲, 杨柳, 袁德智, 王谑菲, 王慧, 孟涛. 普罗布考联合阿托伐他汀钙治疗急性脑梗死的疗效[J]. 中国卒中杂志, 2024, 19(10): 1143-1147.
[3]	宋彦丽, 林杰, 武一平, 李晓晶, 刘改芬, 夏文静, 张玉英, 张晓林, 吕晨冉, 周红, 李凯, 薛斌, 陈玲玲, 张忠波, 彭晓. 邯郸市居民心脑血管病危险因素的流行现状及高血压知晓率、治疗率和控制率的影响因素研究 [J]. 中国卒中杂志, 2022, 17(12): 1360-1365.
[4]	冯皓, 王鑫, 王文娟, 赵性泉. 不同性别老年脑出血患者血脂水平与预后的关系研究[J]. 中国卒中杂志, 2021, 16(10): 1016-1022.
[5]	王春雪，李子孝，王拥军. 2020年国际卒中大会亮点解读（一）[J]. 中国卒中杂志, 2020, 15(03): 228-232.
[6]	王丹丹，王安心，张倩，张怡君，赵性泉. 体检人群新发脑出血相关危险因素分析—— 一项来自社区的观察性研究[J]. 中国卒中杂志, 2019, 14(06): 549-554.
[7]	鲁雨荍, 孔军辉, 张志辰, 张烨, 张卫东, 刘雪梅. 北京市丰台区部分社区卒中高危人群血脂情况及其危险因素研究[J]. 中国卒中杂志, 2018, 13(10): 1039-1043.
[8]	迟晓冬, 苗树川, 李晓红. 非动脉粥样硬化性腔隙性脑梗死病因分析[J]. 中国卒中杂志, 2018, 13(09): 900-902.
[9]	沈东超;吴硕琳;吴佳;王春育;张伟丽. 美国临床内分泌协会：血脂异常管理和动脉粥样硬化预防指南（节选第二部分）[J]. , 2012, 7(10): 807-812.
[10]	沈东超;吴硕琳;吴佳;王春育;张伟丽. 美国临床内分泌协会：血脂异常管理和动脉粥样硬化预防指南（节选第一部分）[J]. , 2012, 7(09): 733-739.
[11]	王苹莉;叶祖森;樊恺;曹云刚;耿媛媛;韩钊;郑荣远. 缺血性卒中患者急性期血清血脂水平与其短期预后的关系[J]. , 2011, 6(10): 784-789.
[12]	李焰生. 缺血性卒中及短暂性脑缺血发作患者的血脂管理 [J]. , 2011, 6(01): 27-32.
[13]	陈兰英;王少兰;张祥建. 血脂、血尿酸及凝血功能与急性脑梗死和脑出血的相关性[J]. , 2008, 3(06): 394-397.
[14]	李焰生. SPARCL试验解读[J]. , 2007, 2(04): 88-90.
[15]	张微微. 重视缺血性卒中后血脂调控的分层管理[J]. , 2007, 2(04): 11-12.